Background High attrition rates, which occur frequently in longitudinal clinical trials of interventions for bipolar disorder, limit the interpretation of results. Purpose The aim of this article is to present design approaches that limited attrition in the Lithium Treatment -Moderate dose Use Study (LiTMUS) for bipolar disorder. Methods LiTMUS was a 6-month randomized, longitudinal multisite comparative effectiveness trial that enrolled bipolar participants who were at least mildly ill. Participants were randomized to either low to moderate doses of lithium or no lithium; other treatments needed for mood stabilization were administered in a guidelineinformed, empirically supported, and personalized fashion to participants in both treatment arms. Results Components of the study design that may have contributed to low attrition (16%) among 283 participants randomized included the use of (1) an intent-to-treat design, (2) a randomized adjunctive single-blind design, (3) participant reimbursement, (4) assessment of intent to attend the next study visit (included a discussion of attendance obstacles when intention was low), (5) quality care with limited participant burden, and (6) target windows for study visits. Limitations The relationships between attrition and effectiveness and tolerability of treatment have not been analyzed yet. Conclusions These components of the LiTMUS design may have limited attrition and may inform the design of future randomized comparative effectiveness trials among similar patients and those from other difficult-to-follow populations.
Introduction
Attrition of participants from effectiveness randomized clinical trials occurs frequently and leads to missed follow-up visits, premature discontinuation of treatment, and incomplete study procedures, complicating the interpretation of study results [1, 2] . Attrition can bias the estimate of the treatment effect and reduce power, precision, and generalizability [3] . Attrition also can introduce treatment selection bias (i.e., treatment actually received is no longer strictly a function of randomization), thereby detracting from a fundamental strength of randomized trials [2] .
In longitudinal intervention studies for bipolar disorder, high attrition rates present a primary obstacle to obtaining adequate power and bias the estimate of treatment response [3] . In a recent review of 14 randomized trials for the maintenance treatment of bipolar disorder, the attrition rates ranged from 19% to 98% (median = 68%), with more study withdrawals by participants prescribed lithium compared to divalproex, lamotrigine, carbamazepine, and olanzapine [4] . These high attrition rates may be due to long follow-up periods (i.e., 6 months to 2.5 years) or to restricting treatment to monotherapy without allowing interventions for residual symptoms. Nevertheless, lithium trials had higher attrition rates.
One study found that 25% of bipolar patients receiving prophylactic lithium treatment discontinued within the first 6 months due to side effects, failure to adhere to treatment instructions, and missed appointments [5] . In a 12-month randomized double-blind maintenance study, Tohen et al. [6] reported a 32.7% attrition rate for lithium monotherapy-treated participants compared to a 26.7% for those treated with olanzapine monotherapy. Randomized participants were seen biweekly for the first 4 weeks of the study and then completed 10 monthly visits as part of a maintenance period. In this study, participants randomized to the lithium monotherapy group also had significantly earlier time to discontinuation (mean = 207 days vs. mean = 303 days, respectively) [6] . In a randomized, double-blind divalproex monotherapy study, the attrition rate was 62% among 197 patients randomized to divalproex monotherapy and 76% among 91 patients treated with lithium [7] . For the first 6 weeks of this study, participants were seen weekly and then biweekly until week 12. Monthly follow-up visits occurred from weeks 12 to 52.
Attrition rates may be lower for acute depression trials compared to maintenance trials for bipolar disorder. Kemp et al. [8] reviewed 14 bipolar studies examining atypical antipsychotics (n = 5), anticonvulsants (i.e., lamotrigine; n = 5), psychostimulant (i.e., modafinil; n = 1), and combination therapy (n = 3) for the treatment of bipolar depression. The attrition rates for these studies ranged from 17% to 66% (median = 36%). Participants may be more motivated for treatment during acute episodes; however, attrition rates were from much shorter study durations (i.e., range = 6-24 weeks, median = 8 weeks) compared to the maintenance trials. Nonetheless, the attrition rates from these bipolar pharmacotherapy studies suggest that a conservative estimate of attrition would be nearly one third of study participants, even for studies with short follow-up periods. Thus, the attrition rate in the Lithium Treatment -Moderate dose Use Study (LiTMUS) for bipolar disorder of 16% is noteworthy. LiTMUS is a 6-month comparative effectiveness trial, with a total of nine study visits, to evaluate the effectiveness of lithium added to optimized treatment (OPT; guideline-informed, personalized pharmacologic treatment).
Our goal is to describe and discuss components of the LiTMUS design that are unique among trials for patients with bipolar disorders and may have limited attrition. Our experience with these design components may inform the development of future randomized comparative effectiveness clinical trials, particularly with patient populations that are vulnerable to treatment nonadherence and study discontinuation. Identification of effective modifications to trial designs could prove to be critical in the evaluation of novel treatments for bipolar disorder.
Lithium Treatment -Moderate dose Use Study Overview
LiTMUS was a 6-month, multisite study to evaluate the effectiveness of lithium added to OPT in comparison to OPT alone. OPT was openly administered, guideline-informed, empirically supported, and personalized pharmacologic treatment based on current symptoms, prior treatment history, and course of disorder. The only requirement for OPT was that participants were prescribed at least one mood stabilizer, as defined by the Texas Medication Algorithm Project [9] . Participants were randomized to receive either open lithium + OPT or OPT without lithium. The primary study outcomes were scores from the Clinical Global Impression for Bipolar Disorder-Severity Index [10] as well as a novel metric assessing the number of Necessary Clinical Adjustments [11] . These adjustments were medication type or dose changes recommended by the study physician to reduce symptoms, optimize response and functioning, or to address intolerable side effects. This metric provided a proxy for both clinical response and tolerability. Secondary and exploratory analyses include symptomatic recovery, quality of life, suicidal behaviors, and moderators of suicidality. The rationale and design for the LiTMUS have been described in detail elsewhere [11] . For this trial, we assumed a 10% attrition rate for the sample size estimation.
Attrition
Recruitment of 283 participants was completed for LiTMUS in September 2009, and the last study participant completed the study on 11 March 2010. A total of 237 participants (84%) completed the study and thus 46 (16%) terminated prior to completing the study, 25 (54%) of whom were in the Li + OPT group (Table 1 and Figure 1 ). Of the participants who exited the study early, the majority (i.e., 32 of 46) were lost to follow-up by personnel at study sites ( Table 2 ). Other main reasons for withdrawing from the study were participants' inability to follow the study procedures and withdrawing consent due to being dissatisfied with their treatment or another aspect of the trial. Although early terminators left the study at each of the study visits, 45% of them completed at least half of the study or 3 months of follow-up. The treatment groups did not differ in their retention rates (χ 2 = 0.45, p = 0.50). Study completers also experienced more adverse events, on average, compared to dropouts (mean = 1.4 ± 1.8 vs. mean = 0.6 ± 1.2; t = 8.72, p = 0.003) due, at least in part, to having a longer period at risk for adverse events and reporting of them. From the discussions with the LiTMUS principal investigators for each study site, feedback from study coordinators, and conversations during site monitoring visits (L.S. and C.K.), we have distilled the main factors that could have contributed to limiting attrition in the LiTMUS.
Strategies adopted to minimize attrition

Intent-to-treat design
LiTMUS used an intent-to-treat study design that allowed participants to remain in the study regardless of whether they were adherent to their (2) Early study terminators = participants who did not complete the study, which was defined as not attending the study exit or Week 24 visit. Nonadherence to Li + OPT = participants who stopped taking the study medication (i.e., lithium). Nonadherence to OPT only = participants who stopped taking a mood stabilizer. randomized study treatment (i.e., Li + OPT or OPT only). This strategy enhanced therapist-provider rapport, an important component of treatment adherence and, thus, of study retention [12, 13] . Study participants were offered clinical treatment regardless of their adherence to the study treatment, indicating a commitment to their clinical care by the study staff. It could be argued that by keeping these participants in the study, we artificially boosted our retention rate. Given that these participants were required to adhere to the other aspects of the study protocol, such as the visit schedule and assessments, our retention rate is still high by historical standards [4, 8] . It also has been suggested that an intent-to-treat design may increase medication nonadherence. Yet in LiTMUS, 10% (n = 29) of participants did not take the randomly assigned study treatment, whereas typically 20%-50% of bipolar patients are not adherent to their study medication [14] . Many trials for bipolar disorder patients purport to use an intent-to-treat design but fail to collect follow-up data from participants once they stop adhering to assigned medications. Thus, these studies present per-protocol rather than intent-to-treat analyses.
This study design feature also provided a more precise estimate of the treatment effect by impacting the statistical analyses. To conduct analyses consistent with the intent-to-treat design, we explicitly distinguished between stopping the randomly assigned treatment regimen and study termination (Table 1) . Thus, in analysis of primary and secondary outcomes, each participant would be classified by random assignment, without regard to medication adherence [2] . In the analyses of one of the two co-primary variables, the Clinical Global Impression for Bipolar Disorder-Severity Index scores will involve construction of mixed-effects models from which one can make valid inferences when willing to assume ignorable attrition, or attrition that is accounted for by covariates or the dependent variable measured prior to dropout [15] .
Randomized adjunctive single-blind design
The participants in both treatment arms received OPT to manage symptoms or episodes as guided by published treatment algorithms [9] . The OPT + lithium group received all available treatments when needed plus lithium or lithium monotherapy. The OPT-only group could receive all available treatments with the exception of lithium. Thus, OPT could be tailored for each participant based on the treatment history and was informed by systematic diagnostic assessments, tracking of symptoms and side effects, and therapeutic blood levels of medications (when clinically appropriate). To optimize treatment, the study physicians were unblinded not only to OPT but also to participants' randomly assigned treatment group. This information allowed physicians to make treatment recommendations without any restrictions, a practice that closely resembles treatment in a community setting.
Many LiTMUS participants commented informally that the unblinded, flexible, and personalized treatment embedded in OPT was a primary reason for entering and staying in the study. Participants preferred this approach to being 'experimented with'. Participants preferred to have very few limitations imposed on their spectrum of treatment options, particularly in the context of a research study, as they perceived such limitations to be a restriction of their care.
A limitation to OPT was that the treatment intensity may have been confounded with one of the two primary outcomes, or the Clinical Global Impression for Bipolar Disorder-Severity Index, given that illness severity not only can influence treatment but treatment also can influence illness severity. As a result, OPT may not have been equivalent across the two groups given the flexibility of dosing and medications. To minimize this potential confound, we summarized the treatment guidelines for bipolar disorder [9] in the LiTMUS Clinical Operations Manual, which were reviewed carefully with each LiTMUS provider. Experts in pharmacotherapy for bipolar disorder (E.F. and M.T.) also reviewed reports each quarter of all participants' medications to verify that participants indeed were receiving OPT (i.e., being prescribed medications consistent with the published treatment guidelines). In the few instances where participants were not receiving OPT (e.g., readministering to a patient a treatment that was previously successful in that same individual, despite inconsistency with published treatment guidelines), the investigators at the National Coordinating Center for LiTMUS contacted the treating study physician. If it was determined that it was not possible to have the participant comply with OPT, a protocol violation was reported but the participant remained in the study.
A second limitation was that group differences may have been due to the study physician's expertise in optimizing treatment. We accounted for this possibility by stratifying randomization by provider. As mentioned, all medication recommendations were reviewed each quarter to ensure that providers were following the treatment guidelines. We also utilized the Necessary Clinical Adjustments to account for the number of medication and dose changes that were due to a worsening course. This measure, designated a primary outcome, allowed us to examine whether the OPT + lithium group required more clinical adjustments and accounted for the flexibility of treatment as part of OPT. A possible drawback for the single-blind design was that study physicians and participants may have favored the lithium arm (lithium + OPT), which would bias outcomes. To minimize bias in the lithium arm, the primary and secondary outcomes were assessed by blinded raters.
Participant reimbursement
Participants were reimbursed $50 per study visit for time and expenses. Each participant agreed to the nine study visits. The baseline visit, or first study visit, often was split into two sessions, each lasting approximately 2 h, to avoid participant fatigue. All of the follow-up visits required approximately 60-90 min of each participant's time, with the exception of the week 12 (mid-treatment) and week 24 (end of treatment) visits, which required approximately 90-120 min. The length of each visit as well as the procedures for each visit (blood draw, selfreport forms, meetings with study staff) were outlined at the time participants consented to enrollment and randomization, so they were aware of the study requirements. Participants who completed all the follow-up visits received $450 for approximately 14 h of their time. We opted to reimburse participants $50 for each study visit as most of the study sites are located in urban environments associated with substantial travel and parking costs. We also elected not to use gas cards, or other, more restrictive forms of reimbursement, given that we wanted to standardize the study procedures across sites and participants who required reimbursement for different expenses, for example, some participants did not drive. Thus, utilizing money as the form of reimbursement ensured that study participants could use the reimbursement for all types of costs, for example, childcare, taxis, public transportation, and missed meals.
Participants across the sites often stated that the study visit reimbursement was an important motivating factor for scheduling and attending followup visits. Evidence of the importance of timely reimbursement was observed at one site, which had to switch the payment procedures halfway through the study. Initially, study personnel at this LiTMUS site reimbursed participants with cash at the end of each visit, but then the payment method changed to a check request system, which required that visit payments arrived several weeks after the visit, resulting in participants' paying outof-pocket for travel time and study-related expenses. After the payment procedures were altered, this site observed an increase in missed visits, suggesting that timeliness and method of reimbursement were influential.
A potential limitation to participant reimbursement was that the amount of money could be considered coercive. After considering the costs associated with the study, such as transportation (highly variable), parking ($10-$25), participant time ($10-$20), and childcare ($15-$40), the amount provided ($50 per visit) was deemed reasonable. Each site's institutional review board approved this amount of reimbursement per study visit. The amount of reimbursement had the potential to attract as study participant individuals with the intent to obtain money as opposed to having an interest in the study purpose. Although it is difficult to determine an individual's reason for participating in a study, we carefully screened individuals. By splitting the first study visit into two sessions (i.e., a screening session and a baseline/randomization session), we were able to determine commitment to the study and acceptance of its procedures.
Intent-to-attend procedures
The Intent-to-Attend scale is a one-item measure that assesses participants' desire to attend the next study visit [16] . At baseline, the intent to complete the trial was also assessed. Intent to attend was rated by participants on a 9-point Likert scale. Whenever a participant responded with a score 4 or below (i.e., less than 'unsure' about attending) on the Intent-to-Attend scale, the research coordinator discussed with the participant the reasons that he or she did not expect to attend the next study visit. The coordinator then discussed with the participant ways to overcome the identified obstacles of future attendance and attempted to accommodate the participant's needs. This study was the first to implement this intent-to-attend procedure and to attempt to influence those who admitted that they were unlikely to attend the next study visit. Future analyses will examine the effectiveness of these procedures.
A possible limitation of the Intent-to-Attend scale is that it may encourage attrition by introducing the possibility of not returning for the next study visit. This concern was expressed by the National Institute of Mental Health's Data and Safety Monitoring Board. Thus, we decided to add the procedures described above for participants who gave scores equal to or less than 4. It is also possible that participants may resent talking about their motives to be in a study or their level of commitment to return for future study visits. The research coordinators were trained on how to administer the procedure for low scores in a sensitive manner. Most participants completed this measure and required no follow-up discussion.
Quality care with limited participant burden
LiTMUS, through the use of OPT, ensured that participants received the best possible personalized treatment for bipolar disorder. This study was also designed to provide close monitoring of participants, as the first five study visits occurred at 2-week intervals, and the remaining four visits occurred monthly. These visits are more frequent than usual pharmacotherapy visits for bipolar disorder, typically every 4-8 weeks. Participants at each study visit also met with at least three members of the local study team (i.e., a study physician, research coordinator, and a blinded rater). At each study visit, data on adverse events, symptoms, functioning, and suicidality were obtained and carefully reviewed; however, we were mindful to exclude scales and information not critical to the primary aims of the study, thereby limiting participant study burden [11] . We also required laboratory monitoring only at Weeks 0, 2, 12, and 24. Furthermore, we attempted to minimize this burden on participants by choosing the duration of the study to be only 6 months, which is shorter than many maintenance trials in bipolar disorder [4] . Our rationale for a 6-month duration was that participants likely would understand the need for an adequate period of follow-up to obtain the needed outcome information, but that a 12-to 18-month study would be less appealing, given the effort involved with attending visits and the possibility of insufficient benefits or adverse effects. We also explained to participants in the lithium + OPT arm that assessment of the tolerability of lithium was a major study goal, so that the lithium dosage would be lowered following adverse effects. Participants reported informally receiving very good care and attention, which likely affected their motivation to complete the study.
A potential drawback with flexible treatment received by experts in the field of bipolar disorder (i.e., OPT) is that it is expensive and does not accurately reflect 'real-world' treatment. A cost-benefit analysis will be conducted to examine this issue. Close monitoring is necessary when investigating pharmacotherapy for bipolar disorder given the tendency for mood to vary over time and the risk of side effects of these study medications [17, 18] . OPT can be considered the gold standard for treatment received in the community. Further training and dissemination of the empirically supported treatment guidelines for bipolar disorder to community and rural caregivers together with methods to diagnose and monitor the disorder are needed.
Target windows for study visits
Consistent with practice in many clinical trials, we utilized 'target windows' for study visits in LiTMUS, which allowed for some flexibility in scheduling them. For the weekly visits, a window of 6 days (i.e., ±3 days from the target date) and for the monthly visits, a window of 10 days (i.e., ±5 days from the target date) were permitted. We also utilized a target window calculator that determined the appropriate window of the eight follow-up study visits to help the site coordinators with scheduling. Participants reported that they appreciated the flexibility provided by a target window, as opposed to a target day, to accommodate their work schedules, other doctors' appointments, vacation time, etc. The use of target windows permitted rescheduling visits that were missed, forgotten, or rescheduled at the last minute by the participant, thereby reducing the number of missed visits. When a study visit during the target window was not possible or failed to occur, then an out-of-window visit could be completed, to ensure continuity of care.
A potential drawback of the flexibility allowed by target windows is that scientific rigor is sacrificed by not having the exact same time interval between each study visit for each participant. However, the mixed-effects models can incorporate the time of actual assessment, not the planned assessment time, in models that assume a linear effect of time. It is also possible that participants may conclude that the actual target date for the study visit is not important and, therefore, be less motivated to attend the scheduled follow-up visits on time.
Discussion
LiTMUS was a longitudinal, randomized multisite comparative effectiveness trial that evaluated lithium as adjunctive treatment for bipolar disorder, a disorder typically associated with high rates of attrition. Despite the rigorous study design, study medication, and patient population, this study yielded an attrition rate (16%) lower than that encountered in other long-term bipolar disorder treatment studies although higher than originally estimated when calculating effect sizes. We have highlighted six possible components of the LiTMUS design that we believe may have contributed to minimizing attrition rates, that is, a randomized adjunctive singleblind design, reimbursement for study-related costs, intent-to-attend procedures, quality care with limited participant burden, and target windows for study visits and discussed potential limitations of each component.
It is possible that we did not recruit a representative bipolar population. Given that participants were required to have an overall Clinical Global Illness Severity score of at least 'mild' at study entry, participants must have been experiencing symptoms that prompted them to seek care. We also made several specific efforts to recruit 'realworld' patients for this study. We paid for all study medication, whether assigned by randomization (lithium) or provided by the physician in accord with guidelines, as needed, to recruit participants from low-income families and/or those without insurance.
The study was conducted at bipolar, or mood disorder, specialty clinics; the treatment and monitoring procedures used in this study may not be feasible in community settings. We advocate empirically supported treatment and monitoring guidelines for bipolar disorder as the standard of care and dissemination of this information [9, 19] . However, guidelines do not address certain aspects of the LiTMUS treatment program which included bimonthly pharmacotherapy and research coordinators assigned to follow each patient. These features of the study may have contributed to the low attrition rate, but do not mimic treatment received in community settings. Although these aspects are typical for pharmacotherapy research studies, the low attrition rate in LiTMUS suggests that specific components of this study could be useful for increasing retention of participants in other pharmacotherapy studies in bipolar disorder. Moreover, compared to typical double-blind placebo-controlled studies for bipolar disorder, participants who enrolled in LiTMUS tended to be more racially and ethnically representative of the general population [20] . They also presented with more Axes I and II comorbidity, a greater number of prior suicide attempts, and higher functional capacity (e.g., higher socioeconomic status and higher employment rates). These data suggest that our strategies to minimize attrition may contribute to strong external validity of LiTMUS results.
LiTMUS did not utilize a run-in phase prior to randomization, which might have lowered our attrition rates further. The Bipolar Affective disorder:
Lithium/ANti-Convulsant Evaluation (BALANCE) study, a longitudinal, open-label multisite trial of 330 participants to compare maintenance treatment with lithium, valproate, or both combined yielded a relatively low attrition rate, or 21% [20] , particularly noteworthy as BALANCE had a 24-month follow-up phase compared to 6 months of follow-up in LiTMUS. However, the BALANCE design included a run-in phase during which treatment response over 4-8 weeks was assessed to ensure that only participants who 'tolerated both drugs in the short term' were randomized. Of the 459 participants initially enrolled in BALANCE, 129 (28%) withdrew from the study during the run-in phase prior to randomization. Given that nearly half the participants, who dropped out of LiTMUS, did so before week 8, such a run-in phase likely would have reduced our attrition rate [20] .
Nonetheless, BALANCE investigators utilized several of the strategies used in LiTMUS, which may account for their low attrition rate.
We observed differences in attrition by site ( Table  1 ), suggesting that other nonstudy-related factors may have affected attrition. For example, the site with the highest attrition rate is located in a state that requires all residents to have health insurance. This requirement afforded participants at this site more treatment options, and in particular, the ability to have clinical care without participating in research. Sites with the lower attrition rates reported that their participants often were able to receive treatment only when enrolled in a research study, due to lack of health insurance or availability of clinical care.
In summary, several design aspects of LiTMUS, a comparative effectiveness trial for patients with bipolar disorder, are believed to have limited attrition. Low attrition rates allow for more precise evaluations of interventions for difficult-to-treat and difficultto-follow populations; innovative approaches may be required to minimize attrition.
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